Drugs / LP-98
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05933824 | Jul 2023 → Apr 2024 | HIV infectious disease | Shanxi Kangbao Biological Product Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07433387 | Jan → Jul 2026 overdue | HIV infectious disease | Shanxi Kangbao Biological Product Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06560489 | Sep 2024 → Jan 2025 | HIV infectious disease | Shanxi Kangbao Biological Product Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-98 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07433387 ↗ |
| Route | Subcutaneous | “administration is by subcutaneous” NCT05933824 ↗ |